Segmental Arterial Mediolysis: An Important but Often Overlooked Cause of Multi-Vessel Thrombosis - 19/05/18

Thomas J. Marrie, MD, Section Editor
El texto completo de este artículo está disponible en PDF.Esquema
| Funding: BAM: National Institutes of Health (1K08HL11207-01A1, 1R56HL131787-01A1, and 1R01HL139613-01); American Heart Association (15GRNT25080016), Pulmonary Hypertension Association, Cardiovascular Medical Research and Education Fund, and Scleroderma Foundation. |
|
| Conflict of Interest: DLB discloses the following relationships. Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Cleveland Clinic, Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (Continuing Medical Education steering committees); Other: Clinical Cardiology (Deputy Editor), National Cardiovascular Data Registry-ACTION Registry Steering Committee (Chair), Veterans Affairs-Clinical Assessment Reporting and Tracking Research and Publications Committee (Chair); Research Funding: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott); Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda. BAM discloses Gilead Sci for investigator sponsored research. |
|
| Authorship: All authors had access to the data and were involved in the writing and preparation of the manuscript. |
Vol 131 - N° 6
P. e231-e234 - juin 2018 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
